Vecuronium (ORG-NC-45)

  • R. D. Miller
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 79)


For several years, anesthesiologists have stated that two new types of neuromuscular blocking drugs (curare-like drugs, muscle relaxants) are needed in clinical anesthesia (Savarese and Kitz 1975). One type of neuromuscular blocking drug would be one that is nondepolarizing with a very rapid onset time (time from muscle relaxant administration until peak effect) and short duration of action, similar to that of succinylcholine, but without the latter drug’s well-known side effects and complications. BW 785U seemed to meet these qualifications (Savarese et al. 1980). However, because of significant histamine release (Rosow et al. 1980), clinical trials with BW 785U were terminated. Thus, the goal of developing this type of neuromuscular blocking drug for clinical anesthesiology has yet to be realized.


Endotracheal Intubation Neuromuscular Blockade Neuromuscular Blocking Drug High Pressure Liquid Chromatography Method Prolonged Paralysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agoston S, Salt P, Newton D, Bencini A, Boomsma P, Erdmann P (1980) The neuromuscular blocking action of ORG NC45, a new pancuronium derivative, in anaesthetized patients. Br J Anaesth 52:53S-60SPubMedCrossRefGoogle Scholar
  2. Baird WLM, Bowman WC, Kerr WJ (1982) Some actions of ORG NC45 and of edrophonium in the anaesthetized cat and in man. Br J Anaesth 54:375–386PubMedCrossRefGoogle Scholar
  3. Barnes PK, Smith GB, White WD, Tennant R (1982) Comparison of the effects of ORG NC45 and pancuronium on heart rate and arterial pressure in anaesthetized man. Br J Anaesth 54:435–440PubMedCrossRefGoogle Scholar
  4. Booij LHDJ, Edwards RP, Sohn YJ, Miller RD (1980) Cardiovascular and neuromuscular effects of ORG NC45, pancuronium, metocurine and d-tubocurarine in dogs. Anesth Analg 59:26–31PubMedGoogle Scholar
  5. Cronnelly R, Fisher DM, Miller RD, Gencarelli PJ, Nguyen-Gruenki L, Castagnoli N Jr (1983) Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. Anesthesiology 58:405–408PubMedCrossRefGoogle Scholar
  6. Crul JF, Booij LHDJ (1980) First clinical experience of ORG NC45. Br J Anaesth 5249S-52SGoogle Scholar
  7. Donlon JV Jr, Savarese JJ, Ali HH, Teplik RS (1980) Human dose-response curves for neuromuscular blocking drugs. Anesthesiology 53:161–166PubMedCrossRefGoogle Scholar
  8. Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF (1981) Relaxation with ORG NC45 during enflurane anesthesia. Anesthesiology 55:A203 (abstract)CrossRefGoogle Scholar
  9. Durant NN, Marshall IG, Savage DS, Nelson DJ, Sleigh T, Carlyle IC (1979) The neuromuscular and autonomic blocking activities of pancuronium, ORG NC45, and other pancuronium analogues, in the cat. J Pharm Pharmacol 31:831–836PubMedCrossRefGoogle Scholar
  10. Fahey MR, Morris RB, Miller RD, Sohn YJ, Cronnelly R, Gencarelli P (1981 a) Clinical pharmacology of ORG NC45 (Nocuron™): A new nondepolarizing muscle relaxant. Anesthesiology 55:6–11PubMedCrossRefGoogle Scholar
  11. Fahey MR, Morris RB, Miller RD, Nguyen T-L, Upton RA (1981b) Pharmacokinetics of ORG NC45 (Nocuron) in patients with an without renal failure. Br J Anaesth 53:1049–1053PubMedCrossRefGoogle Scholar
  12. Fisher DM, Fahey MR, Cronnelly R, Miller RD (1982) Potency determination for vecuronium (ORG NC45): Comparison of cummulative and single-dose techniques. Anesthesiology 51:309–310CrossRefGoogle Scholar
  13. Foldes FF, Yun H, Radnay PH, Badola RP, Kaplan R, Nagashima H (1981) Antagonism of the neuromuscular effect of ORG-NC45 by edrophonium. Anesthesiology 55:A201 (abstract)Google Scholar
  14. Gencarelli PJ, Miller RD (1982) Antagonism of ORG NC45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. Br J Anaesth 54:53–56PubMedCrossRefGoogle Scholar
  15. Gencarelli PJ, Roizen MF, Miller RD, Hoyce J, Hunt TK, Tyrrell JB (1981) ORG NC45 (Nocuron™) and pheochromocytoma: A report of three cases. Anesthesiology 55:690–693PubMedCrossRefGoogle Scholar
  16. Harrison P, Feldman SA (1981) Intubating conditions with ORG NC45. Anaesthesia 36:874–877PubMedCrossRefGoogle Scholar
  17. Krieg N, Crul JF, Booij LHDJ (1980) Relative potency of ORG NC45, pancuronium, al-curonium and tubocurarine in anaesthetized man. Br J Anaesth 52:783–787PubMedCrossRefGoogle Scholar
  18. Marshall RJ, McGrath JC, Miller RD, Docherty JR, Lamar J-C (1980) Comparison of the cardiovascular actions of ORG NC45 with those produced by other non-depolarizing neuromuscular blocking agents in experimental animals. Br J Anaesth 52:21S-32SPubMedGoogle Scholar
  19. Morris RB, Wilkinson PL, Miller RD, Cahalan M, Quasha A, Robinson SL (1981 a) Cardiovascular effects of ORG NC45 (Nocuron™) in patients undergoing coronary artery bypass grafting. Anesthesiology 55:A205 (abstract)Google Scholar
  20. Morris RM, Cronnelly R, Miller RD, Stanski DR, Fahey MR (1981 b) Pharmacokinetics of edrophonium and neostigmine when antagonizing a d-tubocurarine neuromuscular blockade in man. Anesthesiology 54:399–403PubMedCrossRefGoogle Scholar
  21. Nagashima H, Kaplan R, Radnay P, Yun H, Duncalf D, Foldes FF (1981) Relaxation with ORG NC45 during neurolept anesthesia. Anesthesiology 54:A200 (abstract)Google Scholar
  22. Rosow CE, Basta SJ, Savarese JJ, Ali HH, Kniffer KJ, Moss J (1980) BW785U — correlations of cardiovascular effects with increases in plasma histamine. Anesthesiology 53:S270 (abstract)CrossRefGoogle Scholar
  23. Savarese JJ, Kitz RJ (1975) Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology 42:236–238PubMedCrossRefGoogle Scholar
  24. Savarese JJ, Ali HH, Basta SJ, Ramsey FM, Rosow CE, Lebowitz PW, Lineberry CG, Cloutier G (1980) Clinical neuromuscular pharmacology of BW785, an ultra-short-acting nondepolarizing ester neuromuscular blocking agent. Anesthesiology 53:S274 (abstract)CrossRefGoogle Scholar
  25. Sohn YJ, Scaf AHJ, Bencini A, Gregoretti S, Agoston S (1982) The comparative pharmacokinetics of vecuronium (ORG NC45) and pancuronium in man. Fed Proc 41:1336 (abstract)Google Scholar
  26. Somogyi AA, Shanks A, Triggs EJ (1976) Clinical pharmacokinetics of pancuronium bromide. Eur J Clin Pharmacol 10:367–372PubMedCrossRefGoogle Scholar
  27. Somogyi AA, Shanks A, Triggs EJ (1977) The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. Eur J Clin Pharmacol 12:23–29PubMedCrossRefGoogle Scholar
  28. Upton RA, Nguyen T-L, Miller RD, Castagnoli N Jr (1982) Renal and biliary elimination of vecuronium (ORG NC45) and pancuronium in rats. Anesth Analg 61:313–316PubMedCrossRefGoogle Scholar
  29. Van der Veen F, Bencini A (1980) Pharmacokinetics and pharmacodynamics of ORG NC45 in man. Br J Anaesth 52:37S-42SPubMedGoogle Scholar
  30. Walts LF, Stirt JA, Katz RL (1981) A comparison of neuromuscular blocking effects of norcuron and pancuronium. Anesthesiology 55:A210 (abstract)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • R. D. Miller

There are no affiliations available

Personalised recommendations